Latest Ratios: P/E Ratio 162.6x · EV/EBITDA 57.9x · ROE 2.4%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $7.9B | $9.3B | $8.1B | $10.1B | $9.7B | $15.2B | $10.3B | $4.6B | $2.4B | $1.4B | $1.1B |
| Enterprise Value | $8.0B | $9.4B | $8.0B | $10.1B | $9.6B | $14.9B | $9.9B | $4.3B | $2.3B | $1.3B | $1.0B |
| P/E Ratio → | 162.59 | 190.53 | — | 285.40 | 52.26 | 118.23 | 172.64 | 210.23 | 142.54 | 50.39 | 90.65 |
| P/S Ratio | 10.68 | 12.55 | 12.69 | 16.03 | 12.14 | 22.62 | 28.20 | 16.84 | 12.36 | 10.06 | 10.05 |
| P/B Ratio | 3.76 | 4.40 | 4.08 | 5.16 | 5.09 | 8.67 | 6.75 | 4.29 | 3.90 | 2.40 | 6.23 |
| P/FCF | 83.99 | 98.70 | 56.51 | 135.28 | 251.12 | 317.67 | 284.65 | 103.30 | 128.02 | 118.39 | 328.83 |
| P/OCF | 67.17 | 78.93 | 45.91 | 88.98 | 56.53 | 127.43 | 164.91 | 67.72 | 73.18 | 81.39 | 139.73 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.72 | 12.58 | 15.97 | 12.01 | 22.26 | 26.99 | 15.86 | 11.89 | 9.53 | 9.61 |
| EV / EBITDA | 57.91 | 67.90 | 155.12 | 75.45 | 34.18 | 72.57 | 91.23 | 70.33 | 55.26 | 55.03 | 47.14 |
| EV / EBIT | 134.45 | 109.78 | — | 170.53 | 43.70 | 90.57 | 138.55 | 120.94 | 88.80 | 98.32 | 52.27 |
| EV / FCF | — | 100.02 | 56.01 | 134.75 | 248.53 | 312.69 | 272.47 | 97.28 | 123.19 | 112.18 | 314.28 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.1% | 47.1% | 43.3% | 44.0% | 56.9% | 58.3% | 53.1% | 51.1% | 55.7% | 52.5% | 54.9% |
| Operating Margin | 8.1% | 8.1% | -5.5% | 7.5% | 28.0% | 24.9% | 22.2% | 14.8% | 13.4% | 9.9% | 15.3% |
| Net Profit Margin | 6.6% | 6.6% | -4.0% | 5.6% | 23.2% | 19.1% | 16.4% | 7.9% | 8.6% | 20.1% | 11.2% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 2.4% | 2.4% | -1.3% | 1.8% | 10.2% | 7.8% | 4.6% | 2.6% | 2.8% | 7.5% | 8.0% |
| ROA | 1.7% | 1.7% | -0.9% | 1.3% | 7.6% | 6.0% | 3.6% | 2.8% | 12.8% | 13.9% | 5.4% |
| ROIC | 2.2% | 2.2% | -1.4% | 1.9% | 10.1% | 9.7% | 6.5% | 4.6% | 3.7% | 3.3% | 14.0% |
| ROCE | 2.2% | 2.2% | -1.3% | 2.0% | 10.9% | 9.4% | 5.5% | 5.9% | 49.6% | 7.7% | 8.1% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.33 | 0.33 | 0.35 | 0.36 | 0.22 | 0.21 | 0.18 | 0.25 | 0.17 | 0.17 | 0.56 |
| Debt / EBITDA | 4.99 | 4.99 | 13.34 | 5.32 | 1.50 | 1.78 | 2.54 | 4.32 | 2.48 | 4.06 | 4.47 |
| Net Debt / Equity | — | 0.06 | -0.04 | -0.02 | -0.05 | -0.14 | -0.29 | -0.25 | -0.15 | -0.13 | -0.28 |
| Net Debt / EBITDA | 0.90 | 0.90 | -1.38 | -0.30 | -0.36 | -1.16 | -4.08 | -4.35 | -2.16 | -3.05 | -2.18 |
| Debt / FCF | — | 1.32 | -0.50 | -0.53 | -2.59 | -4.98 | -12.18 | -6.02 | -4.82 | -6.21 | -14.55 |
| Interest Coverage | 3.69 | 3.69 | -0.28 | 5.91 | 74.00 | 12.96 | 5.88 | 3.81 | 3.87 | 2.13 | 5.10 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.37 | 8.37 | 8.41 | 6.74 | 2.47 | 2.48 | 2.83 | 13.28 | 2.12 | 9.63 | 8.74 |
| Quick Ratio | 7.12 | 7.12 | 7.28 | 5.51 | 1.88 | 1.99 | 2.53 | 12.15 | 1.80 | 8.08 | 7.57 |
| Cash Ratio | 5.65 | 5.65 | 5.97 | 4.56 | 1.54 | 1.61 | 2.25 | 10.94 | 1.49 | 6.89 | 6.73 |
| Asset Turnover | — | 0.25 | 0.22 | 0.22 | 0.32 | 0.28 | 0.19 | 0.19 | 1.39 | 1.17 | 0.36 |
| Inventory Turnover | 2.29 | 2.29 | 2.52 | 1.75 | 1.45 | 1.51 | 1.81 | 2.41 | 2.03 | 1.72 | 1.91 |
| Days Sales Outstanding | — | 78.41 | 77.16 | 71.67 | 52.94 | 63.92 | 71.14 | 58.98 | 67.26 | 71.68 | 55.98 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.6% | 0.5% | — | 0.4% | 1.9% | 0.8% | 0.6% | 0.5% | 0.7% | 2.0% | 1.1% |
| FCF Yield | 1.2% | 1.0% | 1.8% | 0.7% | 0.4% | 0.3% | 0.4% | 1.0% | 0.8% | 0.8% | 0.3% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $57M | $56M | $56M | $57M | $57M | $54M | $49M | $45M | $39M | $34M |
Bioprocessing inventory destocking cycles
Based on current market data, Repligen trades at a forward P/E of 73.36, a multiple that appears to price in a significant recovery in organic growth rates that exceeds the more modest expectations typically assigned to its diversified life science tools peers in the current environment.
The elevated P/E and EV/EBITDA multiples suggest that investors are paying a substantial premium for the company's 'spec-in' moat and potential for long-term margin expansion. However, this valuation warrants caution, as it implies a high degree of confidence in the company's ability to return to historical growth trajectories while navigating ongoing industry-wide destocking headwinds.
As reported in recent financial statements, Repligen's ROIC has struggled to gain traction, hovering at a marginal 0.6% in 2026Q1, which indicates that the company's recent capital allocation and acquisition strategy have yet to generate returns that exceed the firm's likely cost of capital.
The persistent weakness in ROIC suggests that the integration of past acquisitions and the current overhead structure are diluting the efficiency of invested capital. Investors should monitor whether management can improve asset utilization and margin profiles to drive a meaningful recovery in returns, as current levels remain well below historical performance.
According to quarterly filings, Repligen's asset turnover remains constrained at 0.07, reflecting a business model that is currently burdened by significant inventory levels and a complex manufacturing footprint that has yet to fully normalize following the post-pandemic demand recalibration observed across the bioprocessing sector.
The elevated days inventory outstanding (DIO) figures suggest that the company is still managing the tail end of inventory accumulation, which continues to weigh on overall working capital efficiency. A sustained improvement in the cash conversion cycle will be necessary to demonstrate that the company can effectively convert its specialized product pipeline into consistent cash flow.
Based on the latest balance sheet data, Repligen maintains a robust current ratio of 9.20, providing a substantial liquidity cushion that appears more than adequate to navigate potential supply chain volatility and fund ongoing R&D initiatives without the immediate need for external financing or debt restructuring.
This strong liquidity position serves as a critical defensive feature, allowing the company to maintain its strategic focus despite the recent volatility in operating margins. The high quick ratio further confirms that the firm's liquidity is not overly dependent on the immediate liquidation of inventory, which is a prudent stance given the current industry environment.
The P/E ratio is frequently misapplied to Repligen, as it obscures the significant impact of non-cash amortization charges and stock-based compensation that arise from the company's aggressive acquisition strategy, thereby failing to capture the true underlying cash-generating potential of the core bioprocessing business.
Analysts should prioritize EV/EBITDA or free cash flow metrics to better assess the company's operational performance, as these measures are less distorted by the accounting nuances of recent M&A activity. Relying solely on P/E may lead to an inaccurate assessment of the company's valuation relative to its actual cash-generating capacity.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RGEN stock.
Repligen Corporation's current P/E ratio is 162.6x. The historical average is 88.0x. This places it at the 79th percentile of its historical range.
Repligen Corporation's current EV/EBITDA is 57.9x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 49.6x.
Repligen Corporation's return on equity (ROE) is 2.4%. The historical average is -4.8%.
Based on historical data, Repligen Corporation is trading at a P/E of 162.6x. This is at the 79th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Repligen Corporation has 47.1% gross margin and 8.1% operating margin.
Repligen Corporation's Debt/EBITDA ratio is 5.0x, indicating high leverage. A ratio above 4x may signal elevated financial risk.